Page 1

TOP_October 2011_v6_TOP 10/20/11 10:24 AM Page 1


VOL 4, NO 7



Hallmark Health Hematology and Oncology Center Face-to-Face Communication with Oncology Pharmacists

Oral Chemotherapeutic Agents in Patients with Renal Dysfunction By Melinda Tran, PharmD; Emily Mackler, PharmD, BCOP Department of Pharmacy, University of Michigan Health System, Ann Arbor

By Dawn Lagrosa


ral chemotherapeutic agents have transformed the management of cancer treatment— transitioning the primary location of care to the ambulatory setting and pro-

viding patients with a convenient, noninvasive option to manage their malignancy. Despite the growing availability of oral chemotherapeutic agents, data describing the management of these Continued on page 28


Bevacizumab in Metastatic Breast Cancer: Is This the End of the Line? From left: Oncology Pharmacy Coordinator Meredith Harper, PharmD, BCPS; Oncology Pharmacy Technician Tina Motta, CPhT; System Director of Pharmacy Services Michelle Corrado, PharmD; and Oncology Staff Pharmacist Jon Jankun, RPh.

ffering medical, surgical, and radiation oncology, the Hallmark Health Hematology and Oncology Center provides local access to personalized, comprehensive, high-quality cancer care. Located in Stoneham, Massachusetts, about 7 miles north of Boston, the center is part of Hallmark Health System, which also includes 2 community hospitals, Lawrence Memorial Hospital of Medford and Melrose-Wakefield Hospital.


Continued on page 26

By Joanna Schwartz, PharmD, BCOP Assistant Professor, Albany College of Pharmacy and Health Science Colchester, Vermont Maggie Charpentier, PharmD, BCPS Clinical Associate Professor, College of Pharmacy University of Rhode Island, Kingston


evacizumab (Avastin; Genentech) for metastatic breast cancer may be one of the most widely debated, media-reported, and editorialized agents in oncology. This is certainly understand-

able in an era when targeted therapy such as bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, holds high expectations to provide a much-needed treatment option for Continued on page 14


Genetic Differences Linked to Higher Risk, Severity of Prostate Cancer in African-American Men Understanding Molecular Mechanisms Underlying Disparities May Lead to Strategies for Personalized Treatment

Complimentary Ce



Update on Non-Hodgkin Lymphoma: Alignment of the Current Treatment Landscape and Value-Based Care ConferenCe news

By John Schieszer

WASHINGTON, DC—Genetic differences among African-American and white men seem to be root causes of the prostate cancer disparities between the 2 groups, according to new data. Prostate cancer is the second most


common cancer among men in the United States, with occurrences and mortality rates higher in AfricanAmerican men compared with white men. Studies show that prostate cancer

American Association for Cancer Research . . . . . . . . . . . . . . . . 9 American Society of Clinical Oncology Breast Cancer Symposium . . . . . . . . . . . . . . . . . . . . . 13

Continued on page 10

©2011 Green Hill Healthcare Communications, LLC

reader survey results



Do people receiving treatment talk to you about the cost of their oncology drugs?

Koeller’s Corner

Ne Featuw re

Shooting from the Hip

Will Anybody Be Making Cancer Drugs in the Future? Page 34

Profile for The Oncology Pharmacist

October 2011 Vol4 No7  

The Oncology Pharmacist® features articles written by and for oncology pharmacists and specifically addresses the issues pharmacists and the...

October 2011 Vol4 No7  

The Oncology Pharmacist® features articles written by and for oncology pharmacists and specifically addresses the issues pharmacists and the...